Clinical Trials Browser

Lung Neoplasms × tucotuzumab celmoleukin × Clear all

NCT00016237 2013-10-23

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Phase 1 Completed

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Small Cell Lung Carcinoma